Next-Generation Proteasome Inhibition in Multiple Myeloma

TOP - Supplements
Download PDF
Kim Redic, PharmD, BCPS
Beth Faiman, PhD, APRN-BC, AOCN
Editor in Chief

Supported by funding from Onyx Pharmaceuticals, Inc.

*This publication is not sponsored by, endorsed by, or affiliated with the American Society of Hematology in any way.
 
Articles
Related Items
From the Editor - TON August 2019
Beth Faiman, PhD, APRN-BC, AOCN
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in From the Editors
From the Editor - TON July 2018
Beth Faiman, PhD, APRN-BC, AOCN
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in From the Editors
From The Editor - TON March 2018
Beth Faiman, PhD, APRN-BC, AOCN
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in From the Editors
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in From the Editors
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in Cancer Center Profile
From the Editor
Beth Faiman, PhD, APRN-BC, AOCN
TON - July 2017, Vol 10, No 4 published on July 6, 2017 in From the Editors
Staying Abreast of New Treatments
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent, ASH
Managing Patients with Multiple Myeloma
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent, ASH
Perceptions of Daratumumab Therapy
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent, ASH
Starting a Patient on Daratumumab
Beth Faiman, PhD, APRN-BC, AOCN
Conference Correspondent  published on April 18, 2017 in ASH 2016 - Multiple Myeloma, Hematologic Cancers, Conference Correspondent, ASH
Last modified: July 9, 2015